Regeneron Pharmaceuticals (NASDAQ:REGN) is one of the leaders in the ophthalmic disease therapeutics market. In this article, dear Seeking Alpha readers, I present five factors that explain why I ...
On February 18, 2025, in United States v. Regeneron Pharmaceuticals, the First Circuit held that to establish civil liability under the False ...
Pharma brands achieved the most impressions from ABC and saw a year-over-year increase in impressions from cable channels like Fox News, CNN and MSNBC.
Long Island's six Regeneron Science Talent Search finalists are not yet out of high school and already, they've worked in some of the country's leading laboratories, helped to advance scientific ...
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) stock has gone relatively unnoticed from major headlines in 2024 as GLP-1 makers like Novo Nordisk A/S (NYSE: NVO) and Eli Lilly & Co. (NYSE: LLY ...
Regeneron Pharmaceuticals REGN has outperformed the market over the past 15 years by 12.37% on an annualized basis producing an average annual return of 24.38%. Currently, Regeneron ...
A gene therapy from Regeneron Pharmaceuticals Inc. improved hearing in nearly all deaf children in a clinical trial, results that could allow the company to seek regulatory approval for the one ...
Regeneron's gene therapy study shows improved hearing in children with congenital deafness Regeneron Pharmaceuticals said on Monday its experimental gene therapy showed improved hearing in 10 of ...
It has been about a month since the last earnings report for Regeneron (REGN). Shares have lost about 4.1% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...
Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for priority review the supplemental biologics license application for Dupixent to treat adults with bullous pemphigoid. The ...
In Regeneron Pharmaceuticals Inc.’s phase I/II Chord study of 12 children with genetic hearing loss tied to the variants of the otoferlin gene, 10 out of 11 have showed notable improvements in their ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback